The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT-EHA CAR-T 2019 | CAR T-cell therapy and transplantation for hematological malignancies
Arnon Nagler, MD, from Chaim Sheba Medical Center, Tel-Aviv, Israel, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA). Prof. Nagler reports that despite the promising results of CAR T-cell therapy, the therapy is still in a premature stage for replacing transplant treatments and stresses the need to resolve the limitations of CAR T-cell therapy before it can become a routine intervention.
